Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is still not certain whether it is worth using theophylline in addition to inhaled bronchodilators and corticosteroids to treat obstructive airways disease. This trial was designed to test whether the addition of prescribed theophylline in doses sufficient for sustained optimal steady state plasma concentrations would produce any detectable additional advantage in spirometric or functional variables in these handicapped patients. METHODS: A randomised, double blind, placebo controlled, crossover study of added theophylline treatment was aimed at steady state plasma concentrations of 10 and 17 mg/l, the dose being calculated individually by Bayesian parameter estimation and maintained for six weeks along with the patient's previously prescribed bronchodilators and steroids. Of 20 patients sequentially recruited, 15 provided data that could be analysed. All had chronic obstructive lung disease with a mean forced expiratory volume in the first second (FEV1) up to about 30% of the predicted value and gave no history of being treated with theophylline. The protocol included spirometry, whole body plethysmography, and treadmill exercise. Measurements also included steady state plasma theophylline concentrations and trapped gas volume. Quality of life was assessed by an established questionnaire method covering breathlessness in everyday activities, fatigue, emotional function, and control over the disease. RESULTS: Both target plasma concentrations were achieved. Improvements in peak flow (PEF; mean 20%), trapped gas volumes (38%), two stage vital capacity (15%), distances walked (48%), breathlessness in everyday activities (32%), and fatigue (18%) were found at the higher plasma concentration only. FEV1, forced vital capacity (FVC), emotional function, and control did not change. CONCLUSION: Theophylline treatment with sustained steady state concentrations about 17 mg/l provides worthwhile objective and subjective further benefits for patients handicapped by chronic obstructive lung disease when it is added to bronchodilators and corticosteroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A measure of quality of life for clinical trials in chronic lung disease
Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987) · Thorax · doi:10.1136/thx.42.10.773 · Cited by 1,721
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
“Toxicity is dose-related, which is a problem as most of the benefit occurs when near-toxic doses are given.(116,121)”
BackgroundPulmonary rehabilitation for chronic obstructive pulmonary disease
McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., & Lacasse, Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub3 · Cited by 2,643
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease
Lacasse, Y., Wong, E., Guyatt, G. H., King, D., Cook, D. J., & Goldstein, R. S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04201-8 · Cited by 868
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Lacasse, Y., Goldstein, R., Lasserson, T. J., & Martin, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub2 · Cited by 821
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Managing Cough as a Defense Mechanism and as a Symptom
Irwin, R. S., Boulet, L.-P., Cloutier, M. M., Fuller, R., Gold, P. M., Hoffstein, V., Ing, A. J., McCool, F. D., O’Byrne, P., Poe, R. H., et al. (1998) · Chest · doi:10.1378/chest.114.2_supplement.133s · Cited by 648
Management of Chronic Obstructive Pulmonary Disease
Sutherland, E. R., & Cherniack, R. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030415 · Cited by 563
McKenzie, D. K., & Frith, P. A. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05213.x · Cited by 369
Vogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD
ZuWallack, R. L., Mahler, D. A., Reilly, D., Church, N., Emmett, A., Rickard, K., & Knobil, K. (2001) · Chest · doi:10.1378/chest.119.6.1661 · Cited by 258
Metadata
- Authors
- McKay, S. E., Howie, C. A., Thomson, A. H., Whiting, B., & Addis, G. J.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 1993-03-01
- Volume
- 48
- Issue
- 3
- Pages
- 227-232
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2150729282
- Cited by
- 102
- References
- 1
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.